Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.

Edith P. Mitchell, Roman Perez-Soler, Eric Van Cutsem, Mario E. Lacouture

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.

Original languageEnglish (US)
Pages (from-to)4-9
Number of pages6
JournalOncology (Williston Park, N.Y.)
Volume21
Issue number11 Suppl 5
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Telangiectasis
Hyperpigmentation
Mucositis
Pruritus
Nails
Hair
Clinical Trials
Skin

ASJC Scopus subject areas

  • Oncology

Cite this

Mitchell, E. P., Perez-Soler, R., Van Cutsem, E., & Lacouture, M. E. (2007). Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park, N.Y.), 21(11 Suppl 5), 4-9.

Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. / Mitchell, Edith P.; Perez-Soler, Roman; Van Cutsem, Eric; Lacouture, Mario E.

In: Oncology (Williston Park, N.Y.), Vol. 21, No. 11 Suppl 5, 10.2007, p. 4-9.

Research output: Contribution to journalArticle

Mitchell, EP, Perez-Soler, R, Van Cutsem, E & Lacouture, ME 2007, 'Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.', Oncology (Williston Park, N.Y.), vol. 21, no. 11 Suppl 5, pp. 4-9.
Mitchell, Edith P. ; Perez-Soler, Roman ; Van Cutsem, Eric ; Lacouture, Mario E. / Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. In: Oncology (Williston Park, N.Y.). 2007 ; Vol. 21, No. 11 Suppl 5. pp. 4-9.
@article{e0fa823a97624a098a688f8063ffd6d8,
title = "Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.",
abstract = "This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.",
author = "Mitchell, {Edith P.} and Roman Perez-Soler and {Van Cutsem}, Eric and Lacouture, {Mario E.}",
year = "2007",
month = "10",
language = "English (US)",
volume = "21",
pages = "4--9",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "11 Suppl 5",

}

TY - JOUR

T1 - Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.

AU - Mitchell, Edith P.

AU - Perez-Soler, Roman

AU - Van Cutsem, Eric

AU - Lacouture, Mario E.

PY - 2007/10

Y1 - 2007/10

N2 - This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.

AB - This review summarizes the pathophysiology and clinical presentation of the cutaneous toxicities associated with EGFR inhibition. Such effects include papulopustular reactions, xerosis, pruritus, fissures, nail changes, hair changes, telangiectasias, hyperpigmentation, and mucositis. Most management strategies for these toxicities have been based on anecdotal experience; clinical trials are needed to provide uniform characterization to allow for evidence-based treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=38549149740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549149740&partnerID=8YFLogxK

M3 - Article

C2 - 18154212

AN - SCOPUS:38549149740

VL - 21

SP - 4

EP - 9

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 11 Suppl 5

ER -